News & Updates

Among healthy individuals, a fasting plasma glucose (FPG) concentration within the range of 90–99 mg/dL increases the risk of type 2 diabetes, a new Japan study has found.

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.

Individuals with long-term metabolic syndrome are at increased risk of developing gastrointestinal cancer overall, including colorectal and pancreatic cancers and hepatocellular carcinoma, with the risk increase independent of genetic predisposition, a study has found.

Ertugliflozin, a novel sodium-glucose cotransporter inhibitor, helps reduce glycated haemoglobin (HbA1c), body weight, and fasting plasma glucose (FPG) in patients with type 2 diabetes, reports a recent meta-analysis.

Type 2 diabetes (T2D) patients who are taking multiple medications together are at heightened risk of bone fractures, a study has found.

Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.

A total diet replacement programme produces greater weight loss among people with obesity as compared with support from a practice nurse, with the benefit persisting to at least 3 years, a study has found.

Three surrogate measures of insulin resistance are positively associated with incident major depressive disorder among adults with no history of depression or anxiety disorder, results of the Netherlands Study of Depression and Anxiety (NESDA) have shown. Moreover, the development of prediabetes between study enrolment and 2-year visit also predicts incident major depressive disorder.